Reason for request
Inclusion on the list of medicines reimbursed by National Insurance and approved for use by hospitals in the extension of indication: “Treatment of osteoporosis in postmenopausal women at high risk of fracture.”
Clinical Benefit
| Substantial |
Le service médical rendu par cette spécialité est important dans la prise en charge de l'ostéoporose post-ménopausique chez les patientes à risque élevé de fractures.
|
Clinical Added Value
| minor |
ACLASTA (acide zolédronique) apporte une amélioration du service médical rendu mineure (IV) dans la prise en charge de l'ostéoporose post-ménopausique chez les patientes à risque élevé de fractures.
|
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
m2Fr50xwM5yMW91P
